A glutathione responsive nitric oxide release system based on charge-reversal chitosan nanoparticles for enhancing synergistic effect against multidrug resistance tumor

Niu, XY (Niu, Xiaoyan)^{[ 1 ]} ; Cao, J (Cao, Jing)^{[ 1 ]} ; Zhang, YP (Zhang, Yapei)^{[ 1 ]} ; Gao, XF (Gao, Xuefeng)^{[ 1 ]} ; Cheng, MB (Cheng, Mingbo)^{[ 1 ]} ; Liu, Y (Liu, Yang)^{[ 1 ]} ; Wang, W (Wang, Wei)^{[ 1 ]} ; Yuan, Z (Yuan, Zhi)^{[ 1,2 ]}

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2019, 20, 文献号: 102015

DOI: 10.1016/j.nano.2019.102015

摘要

The combination therapy of nitric oxide (NO) and anticancer drug was developed for reversing multidrug resistance (MDR). In order to avoid NO release during the blood circulation, and realize pinpointed release in the tumor cells, we designed a tumor-specific NO-release system based on 10-hydroxycamptothecin (HCPT)-loaded charge-reversal chitosan nanoparticles and covalently linked phenylsulfonyl furoxan (glutathione (GSH)-responsive NO donor) on the surface. The results showed that only 6.0% of NO was eventually released under physiology condition (pH 7.4 and 2 mu M GSH) within 8 h. In contrast, 93.0% of NO was released within 4 h in the presence of 10 mM GSH. Western blot result displayed the P-glycoprotein expression was significantly decreased by 50.1%. Hence, this system performed remarkable cytotoxicity in vitro and the highest tumor inhibition rate (79.7%) comparing with free HCPT group (20.7%) in vivo. Such GSH-responsive NO-release system is a promising candidate with prominent therapeutic effect against MDR tumor. (C) 2019 Elsevier Inc. All rights reserved.